By SmokerBar Editorial Team

For adult smokers who have tried and failed to quit, understanding the relative risks of different nicotine products is crucial. Among the growing array of smoke‑free alternatives, VELO nicotine pouches have emerged as a leading contender. But the central question remains: Is VELO actually less harmful than cigarettes?

The short answer is yes — based on a growing body of 2025–2026 clinical research, toxicant analysis, and regulatory evaluations, VELO nicotine pouches present a substantially lower health risk profile compared to continued cigarette smoking. However, “less harmful” does not mean “harmless.” Nicotine itself carries real health risks, and VELO is intended only for adult smokers who would otherwise continue using combustible tobacco.

In this comprehensive 2026 guide, we will examine the scientific evidence, compare VELO to cigarettes across key health markers, and help you make an informed decision.

The Fundamental Difference: No Tobacco, No Combustion

The most important distinction between VELO and cigarettes is simple: VELO contains no tobacco leaf and involves no combustion.

Cigarette smoke contains over 7,000 chemicals, including at least 69 known carcinogens. Tar, carbon monoxide, formaldehyde, benzene, and arsenic are all by‑products of burning tobacco. These chemicals are the primary drivers of smoking‑related diseases — lung cancer, chronic obstructive pulmonary disease (COPD), heart disease, and stroke.

VELO nicotine pouches, in contrast, deliver pharmaceutical‑grade nicotine through the oral mucosa without any combustion. The pouches contain:

• Pharmaceutical‑grade nicotine (derived from tobacco but highly purified)

• Plant‑based fibers (for structure and comfort)

• Food‑grade flavorings and sweeteners

• pH adjusters (to optimize nicotine absorption)

Because nothing is burned, VELO does not produce tar, carbon monoxide, or the vast majority of carcinogens found in cigarette smoke. Independent toxicant analysis shows that VELO contains substantially lower levels of harmful and potentially harmful constituents compared to cigarette smoke.

What the 2025–2026 Clinical Research Shows

Recent peer‑reviewed studies provide compelling evidence for VELO’s reduced‑risk profile.

Biomarker Study: Substantial Reductions in Toxicant Exposure

A 2025 clinical study presented at CORESTA and TSRC conferences assessed changes in biomarkers of exposure in adult smokers who switched exclusively to VELO nicotine pouches for five days. The results were striking: the average reduction in toxicant exposure across all VELO users varied between 29% and 97%.

Specifically, exposure to NNAL (a metabolite of the potent lung carcinogen NNK) was statistically significantly reduced in all VELO groups compared to those who continued smoking. The study concluded that these substantial reductions support the potential of oral nicotine pouches as a reduced‑risk alternative for adult smokers who would otherwise continue smoking.

Abuse Liability Study: Lower Addiction Potential Than Cigarettes

A 2025 randomized crossover clinical study published in Frontiers in Pharmacology evaluated the abuse liability of Velo oral nicotine pouches compared to cigarettes and nicotine replacement therapy gum. The findings are significant:

• Mean product liking scores for all Velo ONPs were significantly lower than cigarettes (p < 0.0042), regardless of nicotine level, pouch size, or flavor, but similar to NRT gum.

• Nicotine uptake with Velo was slower (reflected by a longer Tmax) and had lower peak nicotine concentration (Cmax) than cigarettes, but was comparable or slightly lower than NRT gum.

• The study concluded: “Velo ONPs demonstrated an AL profile lower than cigarettes and similar to NRT gum, suggesting a reduced potential for abuse compared to cigarettes.”

In plain English: VELO is less likely to be abused than cigarettes and carries a dependence profile similar to nicotine gum — a product widely used for smoking cessation.

Nicotine Pharmacokinetics Study: Effective Delivery Without Combustion

A 2025 study published in the Journal of Clinical Pharmacology analyzed how Velo nicotine pouches deliver nicotine to the body. The key findings:

• Nicotine pouches delivered nicotine rapidly and efficiently. Maximum blood levels of nicotine (Cmax) were reached quickly, approximating concentrations similar to those obtained from cigarettes, within the first 10 minutes of use.

• Only 1.8% of the nicotine content of a 20 mg pouch was detected in saliva, meaning nearly all nicotine absorption occurs through the lining of the mouth, not the stomach.

• Participants generally rated the pouches as acceptable, supporting their potential role in helping adult smokers switch.

Chris Junker, Group Head of Life Sciences at BAT, commented: “Our study findings and wider research show that oral nicotine pouches can deliver nicotine efficiently and rapidly, similar to the effects of cigarette smoking but with reduced exposure to the toxicants associated with use of cigarettes.”

Toxicant Comparison: VELO vs. Cigarettes

A comparative quantitative analysis of toxicant contents between oral nicotine pouches (including BAT’s VELO products), Swedish snus, and cigarette smoke found that ONPs offer potentially reduced risk of tobacco‑related harm to consumers.

Here is a summary comparison:

Independent research confirms that nicotine pouches “occupy the lowest end of the toxicant risk continuum”.

Cardiovascular and Oral Health Considerations

While VELO is significantly less harmful than cigarettes, it is not risk‑free.

Cardiovascular Effects

Nicotine itself is a stimulant. It temporarily increases heart rate and blood pressure. A 2026 expert consensus report published in the European Heart Journal concluded that no nicotine‑containing product is completely safe for blood vessels or the heart. However, for adult smokers who switch completely from cigarettes to VELO, the cardiovascular risk reduction is substantial — because they eliminate exposure to carbon monoxide, tar, and the thousands of other combustion‑related toxins.

Oral Health

Because VELO pouches are placed directly against the gum tissue, long‑term use may cause localized irritation, gum recession, or dry mouth. A 2026 clinical study found that prolonged exposure (30–60 minutes) may increase vulnerability and caries risk. However, compared to cigarette smoking — which is strongly associated with gum disease, tooth loss, and oral cancer — VELO presents a much lower oral health risk profile.

The reference article correctly notes: “VELO nicotine pouches do not contain tobacco or other carcinogens. While they carry the same risk of addiction, VELO pouches do not cause cancer. Compared to cigarettes, VELO nicotine pouches are safe when used properly.”

The Addiction Question: VELO vs. Cigarettes

One of the most common concerns about nicotine pouches is whether they are as addictive as cigarettes. The 2025 abuse liability study provides clarity:

• VELO has a lower abuse liability profile than cigarettes.

• Nicotine uptake is slower and has a lower peak compared to cigarettes — meaning VELO does not produce the sharp, rapid spikes that make cigarettes so reinforcing.

• Higher‑nicotine VELO pouches (e.g., 10–12 mg) can deliver overall nicotine levels comparable to cigarettes, but the slower absorption curve makes them less reinforcing.

This does not mean VELO is non‑addictive. Nicotine is nicotine, and dependence can develop. But the evidence suggests that VELO is less reinforcing than cigarettes and closer to nicotine replacement therapy gum in its abuse potential.

Who Should Use VELO? And Who Should Not?

VELO is intended for adult smokers and existing nicotine users aged 18+ or 21+ who would otherwise continue using combustible tobacco products.

VELO may be appropriate if you:

• Currently smoke cigarettes and want to reduce your exposure to toxicants

• Have tried to quit smoking using other methods (cold turkey, NRT) and failed

• Are willing to accept the known risks of nicotine use

VELO is NOT appropriate if you:

• Do not currently use nicotine products

• Are under the legal age

• Are pregnant or breastfeeding

• Have a heart condition or high blood pressure without consulting a doctor

• Are a minor or young adult whose brain is still developing

As the reference article states: “Compared to cigarettes, VELO nicotine pouches are safe when used properly” — but proper use means by adult smokers seeking a less harmful alternative, not by non‑users.

2026 Regulatory Landscape: VELO and the FDA

As of April 2026, VELO’s regulatory status in the United States is still evolving. The FDA launched a fast‑track review program for nicotine pouch products, but approvals have stalled as agency scientists weigh concerns about youth uptake and risks to non‑users against potential harm‑reduction benefits for smokers.

According to Reuters reporting on April 1, 2026:

• Applications for VELO (along with newer versions of Zyn and other brands) remain pending despite the fast‑track effort.

• The FDA has already authorized six products under Altria’s on! PLUS label, but reviewers are taking a more cautious stance on other applications where the evidence of net public‑health benefit is viewed as less clear‑cut.

• Specific concerns relate to risks to youth or other non‑users, such as driving addiction in adults who do not already smoke.

BAT has stated that its applications “warrant the agency’s authorization given robust scientific support” and continues to engage constructively with the FDA.

The FDA’s cautious approach reflects the challenge of balancing harm reduction for adult smokers with preventing new nicotine addiction among youth and non‑users. The agency has already authorized 20 Zyn products (in January 2025), demonstrating that nicotine pouches can meet FDA standards. VELO’s applications remain under review, but the scientific evidence supporting its reduced‑risk profile is substantial.

VELO Market Growth in 2026

Despite regulatory uncertainty, VELO is experiencing remarkable growth. British American Tobacco reported a 2.3% rise in annual profit to £11.28 billion ($15.36 billion) in 2025, driven in part by Velo gaining U.S. market share.

Key market statistics as of 2026:

• The U.S. nicotine pouch market reached $8.6 billion in 2025, projected to grow at a 19.4% CAGR through 2035.

• BAT captured roughly two‑thirds of category growth in late 2025, with Velo winning market share from both Altria’s On! and Philip Morris’ Zyn.

• Velo’s success is partly attributed to offering higher nicotine strengths (up to 10–12 mg per pouch) and introductory offers.

• BAT’s new categories (including Velo) accounted for 18.2% of total sales in 2025, up from 17.5% in 2024.

This growth indicates that increasing numbers of adult smokers are turning to VELO as a smoke‑free alternative — a trend supported by the growing body of scientific evidence.

Practical Tips for VELO Users

If you are an adult smoker who has chosen to switch to VELO, here are evidence‑based tips to maximize safety and minimize risks:

1. Switch completely — Dual use (smoking and using pouches) does not provide the same health benefits as complete switching. The biomarker study showed significant toxicant reductions only among those who exclusively used VELO.

2. Start with the lowest effective strength — VELO offers strengths from 4 mg to 12 mg. Begin with a lower strength and only increase if needed.

3. Limit duration — Do not keep a pouch in for more than 30–60 minutes. Prolonged exposure may increase gum irritation.

4. Rotate placement — Alternate between left and right sides of your upper lip to prevent localized gum recession.

5. Stay hydrated — Drink water to counteract the mild dry mouth effect of nicotine.

6. Maintain oral hygiene — Brush twice daily and visit your dentist regularly.

7. Do not exceed recommended daily limits — Most manufacturers recommend no more than 8–10 pouches per day.

8. Store properly — Keep VELO cans in a cool, dry place away from direct sunlight. Do not refrigerate opened cans (condensation can damage the pouches).

The Bottom Line: Is VELO Less Harmful Than Cigarettes?

Based on the totality of 2025–2026 scientific evidence:

Yes — VELO nicotine pouches are substantially less harmful than cigarettes for adult smokers who switch completely.

The evidence supporting this conclusion includes:

• Biomarker studies showing 29–97% reductions in toxicant exposure within five days of switching.

• Toxicant analysis confirming that VELO contains dramatically lower levels of harmful and potentially harmful constituents compared to cigarette smoke.

• Abuse liability studies demonstrating that VELO has a lower potential for abuse than cigarettes and a profile similar to NRT gum.

• Pharmacokinetic studies showing that VELO delivers nicotine efficiently and rapidly enough to satisfy smokers while avoiding combustion‑related toxicants.

However, VELO is not risk‑free. Nicotine is addictive, and long‑term oral health effects require monitoring. The product is intended exclusively for adult smokers who would otherwise continue smoking — not for non‑users, minors, or pregnant women.

As the reference article correctly states: “VELO nicotine pouches do not contain tobacco or other carcinogens. While they carry the same risk of addiction, VELO pouches do not cause cancer. Compared to cigarettes, VELO nicotine pouches are safe when used properly.”

Shop VELO Nicotine Pouches at SmokerBar

At SmokerBar, we carry a full range of authentic VELO nicotine pouches in various strengths (4 mg to 12 mg) and flavors — Polar Mint, Berry Frost, Tropic Breeze, Urban Vibe, and more. Whether you are switching from cigarettes or looking for a reliable smoke‑free alternative, we have the right product for you. All products are sourced directly, stored fresh, and shipped discreetly with age verification (18+ or 21+ depending on local laws).

Browse our VELO collection today — and take a step toward a smoke‑free future.

Disclaimer: This product contains nicotine. Nicotine is an addictive chemical. For adult nicotine users aged 18+ only. This article is for informational purposes and does not constitute medical advice. If you do not use nicotine, do not start. Keep out of reach of children and pets.